Bio/Pharma IPRs: What Separates the Winners From the Losers?

Spotlight: Implications of Just Published New PTAB Rules

The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?

Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.

Topics include:

• Determining trends based on the first 105+ bio/pharma IPR petitions to be filed


• Discovering the most vulnerable types of bio/pharma patents


• Learning how to prosecute bio/pharma patents to withstand IPR


• Employing tactics to help prevent an institution decision


• Understanding more about biosimilar and biologics-related IPRs


• Reviewing updates on PTAB rule changes

Speakers

Stephen Maebius, Partner, IP Department, Foley & Lardner LLP

Kristel Schorr, Partner and Chair, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP

Moderator

Etsuo Doi, Managing Partner, Tokyo Office, Foley & Lardner LLP